AID Cann

Company Overview

Snapshot

Founded in April 1993 by Nir Ben Zvi and Alexander Kozak, AID Cann operates with 11–50 employees. The company has raised a total of $37.65M across 5 funding rounds from 11 investors. In December 2024, AID Cann was acquired by Limited 1498.

Business overview

AID Cann is a vertically integrated medical cannabis company that focuses on the cultivation, manufacture, and distribution of medical cannabis products. The company holds licenses across the entire supply chain, including growing, breeding, nursery operations, product manufacturing, research and development, and distribution. Utilizing a partnership with Amit Farms, AID Cann employs innovative agricultural technologies to cultivate high-quality cannabis and develop proprietary strains. Its IMC-GMP certified manufacturing facility produces a variety of medical cannabis products using ethanol and CO2-based extraction technologies, serving the Health Tech & Life Sciences sector.

Strategic signal

In December 2024, AID Cann was acquired by Limited 1498. This acquisition signals a significant consolidation within the medical cannabis industry, indicating a mature market where strategic exits and integration into larger entities are becoming more common. For investors, this highlights the potential for liquidity events in the sector, while for innovation teams, it suggests a focus on scaling and market reach through M&A.

Company Intelligence Q&A

What was a significant recent corporate development for AID Cann?

In December 2024, AID Cann was acquired by Limited 1498, marking a significant exit for the company.

What strategic alliance did AID Cann announce in May 2021?

In May 2021, AID Cann announced a strategic alliance agreement with DNA Genetics, a vertically integrated Israeli cannabis company.

When did AID Cann acquire Medipharm?

In June 2021, AID Cann acquired Medipharm, a pharmacy.

What was the outcome of the collaboration between Can-Fite and AID Cann?

In January 2020, the collaboration between Can-Fite and AID Cann resulted in the discovery and applied patent for cannabinoid formulations with broad therapeutic effects.

Which investors participated in a July 2019 funding round?

In July 2019, Ido Hagag and Chaim Hurvitz participated in a funding round for AID Cann.